2 article(s) from Onafuye, Hannah
Resulting particle diameters and loading efficiencies for different nanoparticle formulations using...
Jump to Figure 1
SEM images of nanoparticles using emulsion diffusion (ED) or solvent displacement (SD) preparation ...
Jump to Figure 2
Doxorubicin (Dox) release profiles over 24 h for all nanoparticle systems using (A) emulsion diffus...
Jump to Figure 3
Doxorubicin (Dox) drug load and loading efficiency for PLGA nanoparticles (NPs) prepared using a PV...
Jump to Figure 4
(A) Drug load and loading efficiencies as well as (B) particle diameter and PDI for different amoun...
Jump to Figure 5
Release profiles of doxorubicin from PLGA nanoparticles prepared using an unmodified PVA solution a...
Jump to Figure 6
Doxorubicin concentrations that reduce neuroblastoma cell viability by 50% (IC50) when administered...
Jump to Figure 7
Doxorubicin concentrations that reduce UKF-NB-3rVCR1 viability by 50% (IC50) in the absence or pres...
Jump to Figure 8
Beilstein J. Nanotechnol. 2019, 10, 2062–2072, doi:10.3762/bjnano.10.201
SEM confirmed the spherical shape and narrow size distribution of doxorubicin-loaded HSA (100%) nan...
Doxorubicin sensitivity of UKF-NB-3, its doxorubicin-adapted sub-line UKF-NB-3rDOX20 and its vincri...
Effects of doxorubicin (Dox) applied as a solution or incorporated into human serum albumin (HSA) n...
Fold sensitisation to doxorubicin by doxorubicin-bound nanoparticles (NPs). Values are expressed as...
Doxorubicin (Dox) concentrations that reduce neuroblastoma cell viability by 50% (IC50) in the pres...
Beilstein J. Nanotechnol. 2019, 10, 1707–1715, doi:10.3762/bjnano.10.166
Subscribe to our Latest Articles RSS Feed.
Register and get informed about new articles.
Follow the Beilstein-Institut